三叶草生物(02197.HK) 公布，在Ⅰ期临床试验中评估未使用佐剂的二价RSV PreF－三聚体亚单位候选疫苗SCB-1019 (开发基于三叶草生物独有的Trimer-Tag－蛋白质三聚体化疫苗技术平台)与GSK使用AS01E佐剂的RSV疫苗AREXVY进行头对头比较后，在老年人受试者中获得更多积极的免疫原性和安全性数据。
与GSK使用AS01E佐剂的RSV疫苗AREXVY(76.7%)相比，未使用佐剂的SCB1019(16.7%)的局部不良事件(AEs)发生率明显较低。
SCB-1019的耐受性总体良好。SCB-1019的局部和全身不良事件(AEs)总体较轻，与生理盐水安慰剂组相当。
未观察到与疫苗相关的严重不良事件(SAEs)，特殊关注的不良事件(AESIs)或局部不良事件(AEs)导致的停药。
基于上述积极的Ⅰ期临床试验结果，公司计划将在2025年启动临床试验，用于评估SCB-1019 (未使用佐剂的二价RSV-A/B候选疫苗)在RSV疫苗重复接种以及呼吸道联合疫苗的应用情况。(jl/w)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.